Heidi Anne Duerr, MPH

Rebecca Barbee, PA-C, shares tips on addressing the heat wave and its implications when talking with patients.

NRx Pharmaceuticals advances NRX-100, a preservative-free ketamine, through a fast-tracked FDA review for treating suicidal depression and PTSD.

The RECOVER open label trial demonstrated positive results for brilaroxazine for schizophrenia.

Dr Goldberg and Dr Anita share previews of the upcoming ASCP Annual Meeting in Scottsdale, Arizona.

Although there are topics in psychiatry that not exciting, Dr Ghaemi sees plenty of opportunities.

Poster presented at the APA Annual Meeting finds zuranolone effective for anhedonia associated with PPD.

Dr Nassir Ghaemi explores the long-term effects and safety of serotonin reuptake inhibitors, revealing benefits and potential risks.

A nonprofit aims to support clinicians and patients with insurance coverage for evidence-based medicine.

Promising results from a phase 2 study of CPL'36, a novel PDE10A inhibitor, for acute schizophrenia exacerbation was presented at the APA annual meeting.

Can GLP-1 agonists support patients on antipsychotics? Amir Meftah, MD, and colleagues explore its use.

At the APA Annual Meeting, Dana Hilt, MD, PhD, explores the notion of precision psychiatry in depression treatment.

Amir Meftah, MD, discusses the possibility of GLP-1s for addressing metabolic issues associated with antipsychotics.

Dana Hilt, MD, PhD, discusses data on Xanamem’s impact on cortisol and its potential use in MDD at the APA Annual Meeting.

What should you know about the lesser known psychedelics? Clinical insights from Jacob Perlson, MD, MPH, at the APA Annual Meeting.

Etkin describes precision psychiatry data for MDD presented at the Society for Biological Psychiatry Annual Meeting.

Peter J. Weiden, MD, discusses the latest Cobenfy data and implications for schizophrenia treatment.

Joseph Goldberg, MD, discusses the recent joint statement on evidence-based medicine and psychotropic safety.

The FDA decision to remove the clozapine REMs requirement has left many questions. Chelsie Monroe, MSN, APN, PMHNP-BC, sheds some light on it.

Psychiatric Times Editor in Chief John J. Miller, MD, shares thoughts on psychiatry's response to the recent executive order.

Joint statements from leading psychiatric organizations voice concern about impact on patient care from executive orders and budget cuts.

Chelsea Monroe, MSN, APN, PMHNP-BC, discusses the current renaissance in treating schizophrenia.

Determining risks outweigh the benefits, the FDA is removing the clozapine REMS requirement.

Check out these 7 insights and perspectives on recognizing and treating PTSD.

Stephen Mateka, DO, Psychiatric Times' new Child & Adolescent Psychiatry Section Editor, shares thoughts and insights.

A recent phase 2b trial of GH001 showed promising results for treatment-resistant depression, demonstrating rapid and sustained effects with a favorable safety profile.

Although iclepertin was found to be well tolerated, the agent did not meet endpoints.

Psychiatric Times: Supporting clinicians, promoting conversations, and improving patient care over the past 40 years.

Extreme risk protection orders may be an effective suicide prevention tool.